Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.
Induction of antibodies that neutralize a broad range of human immunodeficiency virus type 1 (HIV-1) isolates is a major goal of vaccine development. To study natural examples of broad neutralization, we analyzed sera from 103 HIV-1-infected subjects. Among progressor patients, 20% of sera neutralized more than 75% of a panel of 20 diverse viral isolates. Little activity was observed in sera from long-term nonprogressors (elite controllers). Breadth of neutralization was correlated with viral load, but not with CD4 count, history of past antiretroviral use, age, gender, race/ethnicity, or route of exposure. Clustering analysis of sera by a novel method identified a statistically robust subgrouping of sera that demonstrated broad and potent neutralization activity.
Doria-Rose
Nicole A
NA
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Klein
Rachel M
RM
Daniels
Marcus G
MG
O'Dell
Sijy
S
Nason
Martha
M
Lapedes
Alan
A
Bhattacharya
Tanmoy
T
Migueles
Stephen A
SA
Wyatt
Richard T
RT
Korber
Bette T
BT
Mascola
John R
JR
Connors
Mark
M
D057134:Antibodies, Neutralizing / Q000097:blood* / Q000276:immunology; D016000:Cluster Analysis; D015658:HIV Infections / Q000276:immunology / Q000821:virology; D020276:HIV Long-Term Survivors; D015497:HIV-1 / Q000276:immunology*; D006801:Humans
D057134:Antibodies, Neutralizing